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THIS open-label, prospective, multicentre, 4-week
trial was undertaken to assess the efficacy and
tolerability of twice daily levocabastine eye drops
(0.5 rng/ml), with sodium cromoglycate nasal
spray for the relief of concurrent nasal symptoms
if required, in a total of 233 children with
seasonal allergic conjunctivitis. No correlation
between efficacy, tolerability and age was found.
Investigator assessments revealed that the total
severity of ocular symptoms decreased by 84 +
34% in patients < 12 years and 85 + 30% in
those > 12 years, with corresponding reductions
in the total severity of ocular findings of 84% in
both patient groups over the 4-week treatment
period. Global assessments of therapeutic efficacy
revealed the effect of therapy on ocular
symptoms to be excellent or good in 81% of
patients < 12 years and 82% of those > 12 years
after 2 weeks of treatment, with corresponding
values at the end of the trial of 88% and 82% in
the two groups, respectively. Treatment toler-
ability was considered to bc excellent or good by
94% of patients overall. Application site reactions
were the most common adverse event associated
with ocular levocabastine, occurring in 13% of
patients < 12 years and 9% of those > 12 years.
Twice daily levocabastine eye drops therefore
appear to be effective and well tolerated for the
treatment of seasonal allergic conjunctivitis in
children.
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Introduction
Levocabastine is a novel selective H-receptor
antagonist which has been specifically developed
as eye drops and nasal spray for the topical treat-
ment of allergic rhinoconjunctivitis. Levocabas-
tine is the most potent antihistamine available to
date, being some 15 000 times more potent than
chlorpheniramine on a molar basis and express-
ing antihistaminic activity at doses as low as 0.002
mg/kg.
2 Onset of action is rapid, typically occur-
ring within minutes of instillation, with duration
of effect sufficiently long to4Permit
a convenient
twice daily dosing regimen.’
The efficacy and tolerability of levocabastine
eye drops in the treatment of allergic con-
junctivitis in adults is well documented.5 Com-
parative studies have shown that levocabastine
eye drops administered twice daily are at least as
effective as standard daily doses of oral anti-
histamines
(’-1 and significantly more effective
than sodium cromoglycate four times daily. 11’12
Levocabastine eye drops have also been shown
to be significantly more effective than the topical
antihistamine/vasoconstrictor combination, anta-
zoline/naphazoline, for the treatment of ocular
symptoms,
1 with a tolerability profile compar-
able with that of sodium cromoglycate or
placebo.
14
Preliminary studies in children, involving a total
of 157 patients, have shown that levocabastine
eye drops administered twice daily are at least as
effective and well-tolerated as sodium cromogly-
cate four times daily for the treatment of allergic
1,16 conjunctivitis, both as single agent therapy’
and as an adjunct to oral antihistamine therapy.
The present study was undertaken to assess the
efficacy and tolerability of ocular levocabastine in
the routine treatment of seasonal allergic con-
junctivitis in a much larger group of children and
adolescents. Assessment of any correlation
between efficacy, tolerability and age (< 12
years and > 12 years) was a secondary aim.
Materials and Methods
Study design: Children and adolescents (aged 5
to 16 years) with a history of seasonal allergic
conjunctivitis were eligible for inclusion into this
open-label, prospective, multicentre trial which
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was conducted during the hay fever seasons of
1992 and 1993. All were required to have a
minimum of two characteristic symptoms of
allergic conjunctivitis of at least moderate severity
at the time of entry into the trial. Patients with
soft contact lenses and concurrent disorders
which might have interfered with evaluation of
the study medication were excluded from partici-
pation. In addition, patients were required to dis-
continue use of other antiallergic medication (for
example, oral antihistamines, vasoconstrictors or
corticosteroids) prior to study entry.
All patients received levocabastine eye drops
(0.5 mg/ml), one drop in each eye, twice daily
for a total of 4 weeks. Sodium cromoglycate
nasal spray (20 mg/ml; one spray four times
daily) was provided for use only in patients in
whom concurrent nasal symptoms became mod-
erate or severe. Antazoline and tetryzoline eye
drops or sodium cromoglycate plus xylometazo-
line could be used in patients with severe symp-
toms with a maximum treatment duration of 3
days. No other rescue medication was provided
and use of other medications which could inter-
fere with the evaluation of the study drug was
not permitted during the trial period.
The study design was approved by the local
ethics committee and all children and their
parents provided informed consent.
Ecacy assessments: Ocular symptoms (pruritus,
lacrimation, photophobia and pain), ocular signs
(conjunctival erythema, conjunctival oedema and
eyelid oedema) and nasal symptoms (congestion,
rhinorrhoea, pruritis and sneezing) were as-
sessed by the investigator at the start of the trial
to obtain baseline measurements and then after
2 and 4 weeks of treatment, as well as by the
patients (helped by their parents if necessary) on
a daily basis, using a 4-point scale (0 absent, 1
mild, 2 moderate, 3 severe). In addi-
tion, the investigator provided a global evaluation
of treatment efficacy for both ocular and nasal
symptoms, as well as treatment tolerability, after
2 weeks of treatment and at the end of the trial,
rating therapy as excellent, good, satisfactory or
unsatisfactory.
Statistical analysis: Patients were divided into
two subgroups according to age: < 12 years
(children) and > 12 years (adolescents). In
addition to the mean seventy for each of the
individual symptoms listed above, the following
parameters were calculated and analysed: the
mean total seventy score for ocular symptoms,
the mean total seventy score for ocular findings,
and the mean total seventy score for nasal symp-
toms. Intergroup comparisons were made using
Student’s t-test for parametric data or the chi-
squared test for non-parametric data (5% level of
significance).
Results
A total of 233 patients were enrolled in this
study (177 children and 56 adolescents) by 34
paediatricians. Although all patients are included
in the tolerability analysis, 27 have been excluded
from the efficacy analysis (21 due to insufficient
symptom severity at baseline, one due to age
(< 5 years), two due to a combination of these
two factors and three due to non-compliance
with the study protocol/early drop-out). Patient
demographics for the remaining 206 patients
who were included in the efficacy analysis are
shown in Table 1. As expected, the mean age,
weight and height differed significantly between
the two patient groups (p < 0.001). In addition,
patients < 12 years of age mostly lived in rural
environments, whilst those > 12 years were pre-
dominantly from urban areas (chi-squared, p <
0.01). Symptom severity at baseline was generally
Table 1. Patient demography
< 12 years > 12 years
Number of patients (M/F) 157 (103/54) 49 (32/17)
Mean age in years (range) 7.6 (4-11 )*** 13.4 (12-16)
Mean weight in kg (range) 27.7 (13-56)*** 51.1 (32-115)












FIG. 1. Total symptom severity scores for ocular symptoms
during the 4-week treatment period. **p < 0.01 compared with
baseline values; *p < 0.05 and (*)0.05 < p < 0.1 week 4 com-
pared with week 2.
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FIG. 2. Investigator assessments of global therapeutic efficacy for ocular and nasal symptoms after 2 and 4 weeks of treatment and at
study end-point.
comparable, although ocular findings were sig- Investigator assessments of global therapeutic
nificantly more severe in patients < 12 years efficacy are shown in Fig. 2. After 2 weeks of
compared with those > 12 years (p < 0.05), treatment, the effect of therapy on ocular symp-
while the severity of rhinorrhoea was greater in toms was considered to be excellent or good in
the older patient group (p < 0.01). In all, 140 81% of patients < 12 years and 82% of those
patients were eligible for treatment with sodium > 12 years. The corresponding values at end-
cromoglycate nasal spray, point were 88% and 82% in the two groups,
Significant reductions in symptom severity respectively.
compared with baseline values were apparent in Global therapeutic efficacy for nasal symptoms
both patient groups within 2 weeks of initiation was considered to be excellent or good in 63%
of therapy for all parameters evaluated (p < of patients < 12 years after 2 weeks of treatment
0.01). As shown in Fig. 1, the mean total severity and 68% at study end-point. Corresponding
score for ocular symptoms decreased by 84 + values for patients > 12 years were 65% and
34% in patients < 12 years and 85 4- 30% in 71%, respectively, at these times.
those > 12 years over the 4-week treatment Global evaluations of treatment tolerability in
period, with a 84 _+ 40% reduction in the total the patients included in the efficacy analysis are
severity of ocular signs in both patient groups shown in Fig. 3. At the end of treatment, 94% of
over this period of time. patients in both age groups considered toler-
Pruritus was the most frequent ocular ability to be excellent or good. Adverse events
symptom at baseline reported as moderate to
severe by 89% of patients < 12 years and 92% 00-
of those > 12 years, but moderate to severe
ocular pruritus was only present in 7.7% and
6.3% of patients in the two groups, respectively, 80-
at the end of the trial (end-point values). Simi-
larly, the incidence of patients with moderate to
80"-
severe conjunctival erythema, the most severe ._
ocular sign at baseline, was reduced from 89% to
9% in patients < 12 years and from 88% to 8% g 40-
in those > 12 years over the 4-week treatment
period (end-point values) (p < 0.001).
Analysis of the data generated in the patients’ 20- iil}{i}ili}iii}{i}{iii{ii}{iiiii}{i{ii!}ii}ii}iiiiii}{i}iiiii
diaries revealed similar findings. At the end of the
trial, the mean reduction in total symptom sever-
ity from baseline was 73 + 36% in patients 0
< 12 years _> 12 years
< 12 years and 65 4- 40% in those > 12 years
(baseline scores 2.2 4- 0.7 in patients < 12 [-q Excellent Good
years and 2.0 -I- 0.7 in patients > 12 years; 0 FIG. 3. Investigator assessments of global treatment tolerability
absent, 3 severe), at study end-point.
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Table 2. Incidence of most common adverse events (reported by
at least two patients per group)
< 12years > 12years
Total number of patients 177 56









were reported by 33 (18.6%) of all patients < 12
years and 7 (12.5%) of those > 12 years, with
no statistically significant intergroup differences
in terms of severity or type (Table 2). In all, four
patients (three who were < 12 years and one of
> 12 years) discontinued or interrupted treat-
ment due to adverse events. Reasons for treat-
ment withdrawal in patients < 12 years were
ocular burning in two patients and erythema rash
in another. Treatment was interrupted in one
patient > 12 years due to diarrhoea. The most
common adverse events were ocular burning
(occurring in 9.6% of patients < 12 years and
8.9% of those > 12 years) and/or ocular irrita-
tion (reported by 2.8% of patients < 12 years).
Discussion
The results of this open-label, prospective,
multicentre trial clearly demonstrate that levoca-
bastine eye drops are effective and well-tolerated
for the treatment of allergic conjunctivitis in chil-
dren, with no apparent correlation between effi-
cacy, tolerability and age. The severity of all
symptoms was significantly reduced from base-
line values after 2 weeks of treatment for all
parameters evaluated, with further reductions
apparent by the end of the trial. Overall,
response rates were found to be generally com-
5 13 parable with those reported in adults.- These
findings are supported by those of another
recent paediatric study undertaken to compare
the efficacy and tolerability of topical levocabas-
tine with that of sodium cromoglycate.
8
Drug tolerability is a key factor determining
choice of therapy in children. In this study, levo-
cabastine was found to be well-tolerated with
adverse events reported in 18.6% of children and
12.5% of adolescents. As might be expected from
the route of drug administration, application site
reactions (ocular burning and irritation) were the
most common adverse events reported during
treatment with levocabastine eye drops, occur-
tin8 in 12.4% and 8.9% of patients in the two
groups, respectively. Studies in adults have
shown that the adverse effect profile of topical
levocabastine is comparable with that of sodium
cromoglycate and placebo with ocular irritation
reported in 14% of patients treated with levoca-
bastine eye drops, to date, compared with 15%
for placebo-treated controls.19
In summary, twice daily treatment with levoca-
bastine eye drops appears to be effective and
well tolerated for the treatment of seasonal aller-
gic conjunctivitis in children. Furthermore, com-
parison of the available data suggests that results
of studies undertaken to assess the efficacy and
tolerability of topical levocabastine in adults can
be generalized to paediatric patients. Clinical
experience to date therefore suggests that levoca-
bastine eye drops are an attractive primary
option for the treatment of seasonal allergic con-
junctivitis in this patient population.
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